DB05292ExperimentalSmall molecule
IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by...
- Primary indication
- Ovarian cancerCurator reviewed
Which companies are running trials of IDM-1, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account